Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) has earned an average recommendation of “Hold” from the eleven ratings firms that are currently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $6.07.
MRNS has been the topic of several research reports. Cantor Fitzgerald dropped their price objective on shares of Marinus Pharmaceuticals from $13.00 to $4.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. StockNews.com upgraded Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 4th. Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a report on Monday, September 23rd. Finally, Truist Financial downgraded Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th.
Get Our Latest Stock Analysis on MRNS
Institutional Investors Weigh In On Marinus Pharmaceuticals
Marinus Pharmaceuticals Stock Down 5.1 %
MRNS opened at $0.30 on Friday. Marinus Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $11.26. The stock has a market cap of $16.68 million, a PE ratio of -0.11 and a beta of 1.14. The business has a 50 day moving average of $1.46 and a 200-day moving average of $1.40.
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The firm had revenue of $8.06 million for the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same period in the prior year, the business posted ($0.61) EPS. Equities analysts anticipate that Marinus Pharmaceuticals will post -1.93 EPS for the current year.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Read More
- Five stocks we like better than Marinus Pharmaceuticals
- Business Services Stocks Investing
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Trading Stocks: RSI and Why it’s Useful
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- How Technical Indicators Can Help You Find Oversold Stocks
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.